Post job

Vapotherm main competitors are Abiomed, Dexcom, and Globus Medical.

Competitor Summary. See how Vapotherm compares to its main competitors:

  • Stryker has the most employees (43,000).
  • Employees at Abiomed earn more than most of the competitors, with an average yearly salary of $99,022.
Work at Vapotherm?
Share your experience

Vapotherm vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1999
4.3
Exeter, NH1$68.7M276
1981
4.0
Danvers, MA2$1.0B1,536
1985
4.4
Irvine, CA1$1.6B1,100
1995
4.2
Austin, TX1$378.0M1,000
1941
4.7
Kalamazoo, MI21$22.6B43,000
1989
4.7
Saint Paul, MN3$236.2M780
2008
3.7
-1$1.6M77
1915
4.9
Chicago, IL20$3.0B10,000
1997
4.8
San Diego, CA8$1.2B2,800
-
4.2
Charlotte, NC2$360.0M3,000
1983
4.8
Westbrook, ME92$3.9B9,300
1998
4.3
Arlington, TN3$444.2M5,000
1987
4.8
Pleasanton, CA9$473.4M1,420
-
4.2
Jessup, PA1$3.6M50
1986
4.6
Exeter, PA1$350.0M1,000
Integra Seating
1982
4.5
Walworth, WI26$13.5M18
1919
4.6
Center, PA7$6.6B2,500
1999
4.7
San Diego, CA4$4.0B3,900
2003
4.5
Audubon, PA4$2.5B1,800
1986
3.9
Sunrise, FL1$8.5M375
1967
4.7
Minneapolis, MN3$340.0M700

Rate how well Vapotherm differentiates itself from its competitors.

Zippia waving zebra

Vapotherm salaries vs competitors

Among Vapotherm competitors, employees at Abiomed earn the most with an average yearly salary of $99,022.

Compare Vapotherm salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Vapotherm
$70,200$33.75-
Abiomed
$99,022$47.61-
I-Flow Corporation
$69,708$33.51-
Arthrocare
$64,919$31.21-
Stryker
$69,470$33.40-
Cardiovascular Systems
$64,526$31.02-

Compare Vapotherm job title salaries vs competitors

CompanyHighest salaryHourly salary
Vapotherm
$69,522$33.42
Abiomed
$98,855$47.53
NuVasive
$93,691$45.04
Globus Medical
$74,434$35.79
Dexcom
$73,721$35.44
Stryker
$62,655$30.12
Cardiovascular Systems
$62,113$29.86
MicroPort
$61,632$29.63
rms
$61,611$29.62
Integra Seating
$59,749$28.73
Arthrocare
$59,425$28.57
PolyPid
$59,269$28.49
I-Flow Corporation
$58,689$28.22
Wellnext
$56,071$26.96
Natus
$55,774$26.81
Joerns Healthcare LLC
$55,424$26.65
Olympus
$52,678$25.33
Pride Mobility Products
$52,160$25.08
Mtf
$49,255$23.68
Hillrom
$48,686$23.41

Do you work at Vapotherm?

Does Vapotherm effectively differentiate itself from competitors?

Vapotherm jobs

Vapotherm demographics vs competitors

Compare gender at Vapotherm vs competitors

Job titleMaleFemale
Cardiovascular Systems43%57%
Dexcom50%50%
Abiomed59%41%
Hillrom61%39%
Globus Medical66%34%
Vapotherm69%31%

Compare race at Vapotherm vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
63%7%14%12%3%
7.5
61%12%8%16%4%
9.8
61%14%9%13%3%
9.7
47%25%7%14%7%
9.7
66%13%10%8%3%
9.5
67%11%12%7%3%
9.8

Vapotherm revenue vs competitors

Vapotherm revenue is $68.7M. Among it's competitors, the company with the highest revenue is Stryker, $22.6B . The company with the lowest revenue is PolyPid, $1.6M.

Vapotherm and similar companies CEOs

CEOBio
Michael R. Minogue
Abiomed

I am the Chief Executive Officer, President and Chairman of Abiomed, Inc. (NASDAQ: ABMD), the only medical device company focused solely on heart recovery. At Abiomed, we are driven by our four principles: recovering hearts and saving lives, leading in technology and innovation, growing shareholder value and sustaining a winning culture of putting patients first. As a U.S. military veteran, I also serve as Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization committed to helping military veterans network with industry mentors to discover career opportunities in the life sciences industry.

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

Kevin Ronald Sayer
Dexcom

Kevin Sayer is the Executive Chairman of the board of directors, President and Chief Executive Officer of Dexcom. He joined Dexcom as President and Chief Operating Officer in 2011. In this executive role, Kevin was responsible for research and development, manufacturing, clinical, regulatory, finance, sales and marketing functions. During his tenure with Dexcom, he has been instrumental in leading the development of new technology, including the Dexcom G5 Mobile CGM System, the Dexcom G4 PLATINUM System with Share and several other product launches in the US and Europe. Prior to joining Dexcom, Kevin served as Chief Financial Officer of Biosensors International, a medical technology company focused on the development, manufacturing and commercialization of medical devices used in interventional cardiology and critical care procedures. Kevin also served as CFO of MiniMed, Inc. from 1994 until its acquisition by Medtronic, Inc. in 2001. Kevin received his master's and bachelor’s degrees in Accounting and Information Systems from Brigham Young University.

Daniel T. Scavilla
Globus Medical

A Strategic and Operational CFO with broad & deep geographic and business experience in Pharmaceutical, Biotech, Medical Device & Consumer Goods leading international markets worldwide in Financial operations, General Management, Information Technology, Procurement & Facilities. A strategic thinker partnering with leadership to develop long-range plans and deliver business & financial results through fact-based decision support, developing diverse cross-functional talent and implementing comprehensive metrics. Identify and sponsor change through P&L efficiencies, improved cash flow and new business models, fueling profit growth and margin expansion. Appling this approach to lead “beyond the numbers” with broad business acumen to impact the business.Recognized as a thought leader and business partner with a hands-on approach going beyond the financial leader role, a strong communicator who sorts through complexity and asks the right questions, willing to challenge the status quo & lead transformational change. Develop global finance organizations, placing leaders beyond the finance function.Experienced Management Board member of various sized healthcare, life science and consumer goods companies from start-up to multi-billion dollar global market leaders, driving high-growth businesses, improving turn-arounds and acquisition integration. Led financial organizations from 5 to 200 employees.Areas of expertise:Growth Strategies | Global Leadership | Board Member | Fact-Based Decision Support | Strategic & Financial Planning | Worldwide P&L Management | International Finance | Cost Accounting | Competitive Intelligence | Talent DevelopmentAdditional skills:Internal Financial Controls | Financial & Portfolio Analysis | Tax Planning | International Treasury Functions | Capital Structure & Cash Management | Mergers & Acquisition | Project Management | Investor Relations | New Product Launches | Acquisition Integration

John P. Groetelaars
Hillrom

Jonathan J. Mazelsky
IDEXX

Mr. Mazelsky was appointed President and Chief Executive Officer of IDEXX on October 23, 2019. Prior to his appointment, Mr. Mazelsky served as IDEXX's Interim President and Chief Executive Officer beginning on June 28, 2019. Prior to his appointment as Interim President and Chief Executive Officer, he was an Executive Vice President responsible for our North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including our IDEXX VetLab® in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business. He joined IDEXX in August 2012 as Executive Vice President. Previously, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

Jonathan Kennedy
Natus

Jonathan Kennedy has served as Chief Executive Officer and Director of Natus since July 2018. Prior to his appointment as CEO, Mr. Kennedy served as the Company’s Chief Financial Officer since April 2013 and served as General Manager of Natus’ Newborn Care Business Unit from April 2017 to February 2018. Before joining Natus, Mr. Kennedy was Chief Financial Officer of Intersil Corporation, a global semiconductor manufacturer, since 2009. Prior to that, he was Intersil’s Corporate Controller since 2005. Before joining Intersil, Mr. Kennedy held management roles in Finance and Information Technology with Alcon Inc., a manufacturer of medical devices and pharmaceuticals for the ophthalmic industry and Harris Corporation, a diversified global technology company. Mr. Kennedy served on the Board of Directors of Iradimed Corporation a manufacturer of MRI compatible medical devices from 2016 to 2019. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida.

Chris Barry
NuVasive

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Kevin A. Lobo
Stryker

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

Kook Books is a Chief Executive Officer at I-Flow and is based in Haven, Kansas.

What employees say about Vapotherm's competitors

Employee reviews
profile
5.0
A zippia user wrote a review on Jun 2021
Pros of working at Vapotherm

It’s a rewarding job, the product we manufacture helps people all over the world.

Cons of working at Vapotherm

Unclear career path and poor communication.

Vapotherm benefits

Work/personal life balance. Very good schedule

Is this useful?
Work at Vapotherm? Share your experience

Vapotherm competitors FAQs

Search for jobs